Best Peptides for Recovery

Recovery peptides have become some of the most sought-after compounds in regenerative medicine. Athletes, surgical patients, and anyone dealing with slow-healing injuries are turning to peptides that target specific phases of tissue repair, from reducing acute inflammation to promoting angiogenesis and collagen deposition. The appeal is straightforward: faster, more complete healing than the body achieves on its own.

The peptides in this guide work through distinct biological mechanisms. Some accelerate structural repair at the cellular level by upregulating growth factor receptors or promoting new blood vessel formation. Others modulate the inflammatory response that, when left unchecked, can stall recovery for weeks or months. A third category supports healing indirectly by elevating growth hormone and IGF-1, both central to the body's regenerative processes. Understanding which mechanism matches your situation is the key to choosing the right peptide.

An important caveat: No recovery peptide discussed here is FDA-approved for human therapeutic use. The evidence base is predominantly preclinical. Human clinical data, where it exists, is limited to small pilot studies and case series. These compounds should only be considered under physician supervision.

How We Ranked These Peptides

Our rankings weigh four factors:

1. Strength of evidence. Peptides with systematic reviews, multiple independent research groups, and any human data rank higher than those supported by isolated studies.
2. Mechanistic breadth. Peptides that engage multiple recovery pathways, inflammation control, angiogenesis, cell migration, collagen synthesis, rank above those addressing a single mechanism.
3. Safety profile. Preclinical toxicology data, reported side effects, and severity of potential risks all factor into placement.
4. Clinical experience. Practitioner protocols and documented user outcomes provide practical context beyond controlled studies.

1. BPC-157, Best Overall for Tissue Repair

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein in human gastric juice. It holds the top position because no other recovery peptide matches its combination of mechanistic breadth and research volume, over 100 published studies across multiple tissue types.

A 2025 systematic review in HSS Journal identified 36 studies examining BPC-157 in orthopaedic contexts, finding improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bone injury models. Its mechanisms include upregulation of growth hormone receptors in tendon fibroblasts, promotion of angiogenesis through the nitric oxide system, reduction of inflammatory cytokines, and enhanced cell survival under oxidative stress.

BPC-157 is particularly notable for tendons and ligaments, tissue types notorious for slow healing due to limited blood supply. Research demonstrates that BPC-157 significantly accelerates tendon explant outgrowth and increases cell survival under conditions that normally trigger apoptosis.

Best for: Tendon injuries, ligament sprains, GI healing, muscle strains, post-surgical recovery.

Typical dosage: 250 to 500 mcg per day via subcutaneous injection near the injury site. Oral administration is viable for GI applications. Protocols typically run 4 to 8 weeks.

Limitations: As of early 2026, only three published human studies exist. No randomized controlled trials have been completed. BPC-157 is prohibited by WADA and is not FDA-approved.

2. TB-500, Best for Systemic Recovery

TB-500 is a synthetic peptide based on a 7-amino-acid active region of thymosin beta-4, a naturally occurring 43-amino-acid protein involved in cell migration and tissue repair. Where BPC-157 excels at targeted local repair, TB-500 circulates systemically and supports healing across multiple injury sites simultaneously.

Thymosin beta-4 regulates actin, the structural protein cells need to migrate into damaged tissue. By sequestering actin monomers, TB-500 promotes cell migration essential for wound closure and tissue remodeling. It also stimulates angiogenesis and satellite cell proliferation, the muscle stem cells responsible for regenerating damaged fibers.

Animal studies showed topical or intraperitoneal thymosin beta-4 increased wound re-epithelialization by 42% at 4 days and up to 61% at 7 days versus controls. Skeletal muscle injury models demonstrated accelerated fiber regeneration and reduced fibrotic scarring. Phase 2 clinical trials for chronic wounds, including venous stasis ulcers, demonstrated accelerated healing with acceptable safety profiles.

Best for: Multi-site injuries, muscle tears, flexibility restoration, chronic wounds, extensive post-operative recovery.

Typical dosage: Loading phase of 2 to 2.5 mg twice weekly for 4 to 6 weeks, then maintenance at 2 mg once weekly. TB-500 does not require local injection due to its systemic distribution.

Limitations: Prohibited by WADA under S2 as a non-Specified Substance. Not FDA-approved. A positive test typically results in a 4-year ban from WADA-compliant sports.

3. GHK-Cu, Best for Skin and Connective Tissue

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide that plays a role in wound healing, collagen synthesis, and tissue remodeling. Unlike BPC-157 and TB-500, GHK-Cu has established human clinical evidence, particularly for skin applications.

In randomized trials, GHK-Cu increased collagen production in 70% of volunteers, outperforming both vitamin C and retinoic acid. A double-blind trial showed that twice-daily application for 8 weeks reduced wrinkle volume by 55.8% and depth by 32.8% versus control. Clinical trials on diabetic ulcers and Mohs surgical wounds demonstrated significantly improved re-epithelialization. At the cellular level, GHK-Cu stimulates blood vessel and nerve outgrowth and modulates over 4,000 human genes involved in tissue repair.

Best for: Surgical wound healing, scar reduction, skin quality, post-procedure recovery (laser resurfacing, microneedling).

Typical dosage: Topical at 1 to 2% concentration twice daily. Injectable at 1 to 2 mg subcutaneously, 2 to 3 times per week (limited by a plasma half-life of approximately 30 minutes).

Limitations: Strongest evidence is topical. Short half-life limits systemic effectiveness. Copper complex stability can be affected by environmental factors during storage.

4. KPV, Best for Inflammation-Driven Recovery

KPV (Lysine-Proline-Valine) is a tripeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH) that exerts anti-inflammatory activity equal to or greater than the full-length molecule. It is most relevant when chronic inflammation is the primary barrier to healing.

KPV inhibits NF-kB and MAP kinase signaling at nanomolar concentrations by stabilizing IkB-alpha and suppressing nuclear translocation of p65RelA. This shortens the inflammatory cascade, allowing tissue to transition into repair phases more quickly. The peptide enters cells via the hPepT1 transporter, expressed in both immune and intestinal epithelial cells.

Oral KPV reduced severity of experimentally induced colitis in animal models with significant decreases in pro-inflammatory cytokines. Wounded epithelial layers showed dose-dependent improvements in recovery rates. Bronchial epithelial cell studies confirmed inhibition of TNF-stimulated NF-kB activity.

Best for: Gut inflammation, intestinal barrier recovery, chronic inflammation impeding repair, skin inflammation.

Typical dosage: 200 to 500 mcg per day via subcutaneous injection or oral capsule.

Limitations: Earlier-stage research than BPC-157 or TB-500. No completed human clinical trials. Mechanism is anti-inflammatory rather than broadly regenerative, so it works best combined with structural repair peptides.

5. Growth Hormone Peptides, Best for Overall Regeneration

Growth hormone secretagogues elevate GH and IGF-1, both central to protein synthesis, collagen formation, cellular repair, and immune function. They support recovery indirectly but substantially. Three are particularly relevant:

Sermorelin is a GHRH analog that stimulates pituitary GH release in a physiological pulsatile pattern. It has the longest clinical track record, having been previously FDA-approved for pediatric growth hormone deficiency. Typical dose: 200 to 300 mcg before bedtime. Full Sermorelin guide.

Ipamorelin is a selective GHRP that induces GH release through ghrelin receptors without significantly affecting cortisol or prolactin, a clean profile well-suited to recovery applications. Typical dose: 100 to 300 mcg, 1 to 3 times daily. Full Ipamorelin guide.

CJC-1295 is a modified GHRH analog that sustains elevated GH and IGF-1 longer than Sermorelin. Combined with Ipamorelin, it acts on separate pituitary pathways for synergistic GH release, one of the most widely used peptide stacks. Typical dose: 100 mcg, 1 to 3 times daily. Full CJC-1295 guide.

Best for: Training recovery, reducing DOMS, supporting collagen deposition, improving sleep quality.

Limitations: Indirect mechanism with slower timelines. Require cycling (8 to 12 weeks on, 4 weeks off). GH elevation carries theoretical risks with active malignancies or uncontrolled diabetes.

The Wolverine Stack: BPC-157 + TB-500

The Wolverine Stack is the most popular recovery peptide combination, named for its reputation for accelerated healing. It pairs the targeted local repair of BPC-157 with the systemic regenerative reach of TB-500.

The rationale is mechanistic complementarity. BPC-157 upregulates growth factor receptors, promotes angiogenesis via the nitric oxide system, and reduces inflammatory cytokines, all localized at the injury site. TB-500 facilitates cell migration through actin regulation and mobilizes satellite cells for muscle regeneration on a systemic level. Together, BPC-157 creates a favorable local healing environment while TB-500 supplies the cellular resources needed to rebuild the tissue.

Standard Protocol

Loading Phase (Weeks 1 to 4):

• BPC-157: 250 to 500 mcg per day, subcutaneous, near the injury site
• TB-500: 2 to 2.5 mg twice weekly, subcutaneous, abdomen or deltoid

Maintenance Phase (Weeks 5 to 8):

• BPC-157: 250 mcg per day
• TB-500: 2 mg once weekly

Cycle duration: 8 to 12 weeks, then 4 weeks off. Both peptides are water-soluble and compatible in bacteriostatic water, though some protocols recommend separate syringes.

This combination has not been evaluated in controlled clinical studies. The protocol is derived from practitioner experience, not randomized trials. See our Peptide Stacking Guide for more combination protocols.

Safety and Legal Considerations

Regulatory status. No recovery peptide in this guide is FDA-approved for human therapeutic use. As of early 2026, the FDA has initiated reclassification proceedings that may restore legal compounding pathways for certain peptides under physician prescription. This does not constitute FDA approval. Both BPC-157 and TB-500 are prohibited by WADA. BPC-157 metabolites are detectable in urine for up to 4 to 5 days, and TB-500 carries a 4-year ban upon positive test.

Quality risks. Unregulated peptide products may be mislabeled, underdosed, or contaminated with heavy metals or endotoxins. Third-party certificates of analysis are essential. See our purity testing guide and COA guide.

Monitoring. Baseline blood work should include a complete metabolic panel, lipid profile, fasting glucose and insulin, IGF-1, and CBC. Repeat at 4 to 6 weeks.

Known risks by peptide:

• BPC-157: Potential immunogenicity; unknown long-term effects. No acute toxicity in animal studies.
• TB-500: Theoretical tumor angiogenesis concern. Limited human safety data.
• GHK-Cu: Well-tolerated topically. Theoretical copper accumulation with prolonged injectable use.
• KPV: Limited safety data. Caution in immunocompromised individuals.
• GH peptides: May affect glucose metabolism. Contraindicated with active malignancies.

Conclusion

BPC-157 leads the field with the broadest preclinical evidence for direct tissue repair. TB-500 provides systemic reach for multi-site recovery. GHK-Cu delivers the strongest human clinical evidence for skin and connective tissue. KPV addresses the inflammatory bottleneck that stalls healing. Growth hormone peptides support recovery indirectly through elevated GH and IGF-1. The Wolverine Stack, BPC-157 combined with TB-500, remains the most popular recovery protocol for its complementary mechanisms.

Every peptide in this guide lacks the comprehensive human clinical data that would establish definitive efficacy and safety. The evidence is promising but predominantly preclinical. Physician supervision, quality sourcing, and baseline blood work monitoring are not optional. They are the minimum standard for responsible use.